# A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

> **NCT00082212** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 25 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT00082212
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Due to lack of sufficient efficacy.
- **Last updated:** 2010-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082212, "A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00082212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*